A Phase 1 Study of JNJ-88549968 in People With Myeloproliferative Neoplasms

Full Title

A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms

Purpose

Researchers want to find the best dose of JNJ-88549968 to use in people with myeloproliferative neoplasms. Examples of these cancers include myelofibrosis and essential thrombocythemia. In addition, their cancers have a change (mutation) in the CALR gene.

JNJ-88549968 binds to one protein on cancer cells and to another on immune cells called T cells. JNJ-88549968 may strengthen your immune system’s ability to fight cancer cells by helping your own cells to destroy your cancer. It is given as a subcutaneous (under the skin) injection.

Who Can Join

To join this study, there are a few conditions. You must:

• Have a myeloproliferative neoplasm such as myelofibrosis or essential thrombocythemia that has a CALR mutation.
• Not be able to be successfully treated using standard therapies.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Raajit Rampal’s office at 646-608-3746.